FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive|HER2/Neu Negative|Male Breast Carcinoma|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer
Interventions: DRUG: Fluorothymidine F-18|PROCEDURE: Positron Emission Tomography|OTHER: Laboratory Biomarker Analysis|DRUG: Run-in (short pre-surgery course) of endocrine-targeted therapy
Sponsor: University of Washington
Collaborators: National Cancer Institute (NCI)